Picture: Andera Partners

Jan Van den Bossche becomes the 20th partner of Andera Partners. He joined the Life Sciences team at the beginning of July to accelerate the deployment of its BioDiscovery 6 fund.

© Lonza Group Ltd.

Large CDMO Lonza to build a new large-scale, commercial drug product facility including fill and finish to support customers across the entire product life cycle in Switzerland, investment of CHF500m.

Picture: Charnwood Molecular

Lee Patterson joins UK-based Charnwood Molecular as new CEO. After nearly 25 years at UK-based Charnwood Molecular, Prof. Steve Allin has stepping down as CEO. He will remain as an investor and Board advisor.

Ecotec is part of the Gram-Negative Antibacterials NOW (GNA NOW) consortium within the Innovative Medicine Initaitive's AMR Accelerator. © AdobeStock

Evotec, pharma giant Boehringer Ingelheim, and IVD specialist bioMérieux have launched a €40m joint venture to fight Antimicrobial Resistance (AMR).

Production at Pierre Fabre Médicaments. © Pierre Fabre

French drugmaker Pierre Fabre Médicaments will pay $75m for an exclusive licence to to commercialise Urovant Sciences’ drug vibegron for the treatment of overactive bladder in Europe.

German Regional Court in Düsseldorf. © Justiz NRW

German mRNA vaccine developer CureVac, whose COVID-19 vaccine was not effective, on Monday sued BioNTech/Pfizer for infringement of four patents.

© Ipsen

Shares of French drugmaker Ipsen fell by 4.4% at Euronext Paris after the company announced to take over US cancer specialist Epizyme Inc. for $247m.

Ambrosia Bio co-founder and CEO Ziv Zwighaft (left) and Olivier Rolland, Executive Director at TWB. © Toulouse White Biotech

At the end of the TWB Start-up day, which was attended by more than 200 biotech professionals, two industrial biotechnology companies were awarded prizes worth €50,000.

BioNTainers. © BioBTech SE

BioNTech SE has announced it is going to ship the first containers for mRNA malaria vaccine production from this year’s end toKigall.

© Canify AG

In an effort to become a major player in Europe’s growing pharmaceutical-grade cannabis market, Danish Canify AS and Bavaria Weed GmbH merge to form Canify AG.